REVIRAL
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.
REVIRAL
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2011-01-01
Address:
Stevenage, Herefordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.reviral.co.uk
Total Employee:
11+
Status:
Active
Contact:
44 29 2078 1795
Email Addresses:
[email protected]
Total Funding:
121 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Biotrics Bioimplants
Biotrics Bioimplants is a biotechnology company that develops biomaterials for oral tissue regeneration.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Andera Partners
Andera Partners investment in Series C - ReViral
Perceptive Advisors
Perceptive Advisors investment in Series C - ReViral
CR-CP Life Science Fund
CR-CP Life Science Fund investment in Series C - ReViral
Green Sands Equity
Green Sands Equity investment in Series C - ReViral
OrbiMed
OrbiMed investment in Series C - ReViral
New Leaf Venture Partners
New Leaf Venture Partners investment in Series C - ReViral
Novo Holdings
Novo Holdings investment in Series C - ReViral
Brace Pharma
Brace Pharma investment in Series C - ReViral
OrbiMed
OrbiMed investment in Series B - ReViral
Novo Ventures
Novo Ventures investment in Series B - ReViral
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-17 | ReViral Appoints Brett Haumann as Chief Medical Officer |
Official Site Inspections
http://www.reviral.co.uk Semrush global rank: 2.15 M Semrush visits lastest month: 9.33 K
- Host name: 147.154.27.36
- IP address: 147.154.27.36
- Location: Seattle United States
- Latitude: 47.6109
- Longitude: -122.3303
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98101
More informations about "ReViral"
ReViral - Crunchbase Company Profile & Funding
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion …See details»
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus ...
Apr 7, 2022 · REVIRAL1 is a global three-part adaptive study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, antiviral effects, and clinical effect of single and multiple oral …See details»
ReViral Company Profile 2024: Valuation, Investors, Acquisition
Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds.See details»
ReViral Ltd. - life-sciences-europe.com
Jan 1, 2011 · ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an …See details»
ReViral - LinkedIn
ReViral – Innovative therapies for viral diseases ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel...See details»
Biotech firm ReViral acquired by Pfizer in £412m deal
Apr 26, 2022 · ReViral, which has run a research facility at Sedgefield's NETPark since 2016, will strengthen Pfizer's infectious diseases capabilities and will benefit from the multi-national's commercialisation expertise.See details»
Pfizer acquires ReViral - 2022-04-07 - Crunchbase
Apr 7, 2022 · reviral.co.uk — Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic CandidatesSee details»
Pfizer boosts respiratory drug portfolio with ReViral …
Apr 7, 2022 · Pfizer Inc said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million including milestone payments, to gain access to experimental drugs against the...See details»
ReViral - Org Chart, Teams, Culture & Jobs - The Org
ReViral is a UK-based biotechnology company developing first-in-class drugs to treat RSV infections. It takes less than ten minutes to set up your company page. It’s free to use - try it …See details»
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Apr 7, 2022 · Founded in 2011, ReViral is a London, UK and Research Triangle Park, North Carolina based privately held clinical-stage biopharmaceutical company focused on …See details»
Pfizer Completes Acquisition of ReViral
Jun 9, 2022 · ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the …See details»
Andera Partners to sell its Life Sciences’ portfolio company ReViral …
Apr 7, 2022 · Under the agreement, ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral …See details»
Pfizer to Acquire ReViral for Up to $525M, Expanding RSV Pipeline
Apr 7, 2022 · Pfizer has agreed to acquire ReViral, a developer of antiviral therapeutics targeting respiratory syncytial virus (RSV), for up to $525 million, the companies said today, in a deal …See details»
Andera Partners to sell its Life Sciences’ portfolio company ReViral …
Apr 7, 2022 · Under the agreement, ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral …See details»
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Apr 22, 2005 · COPENHAGEN, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its portfolio company ReViral Ltd (ReViral), has …See details»
Sussex collaborator company ReViral to be acquired by Pfizer
May 16, 2022 · ReViral has now entered into an agreement to be acquired by Pfizer for a total consideration of up to US$525 million. The proposed transaction is subject to customary …See details»
ReViral Company Profile - Office Locations, Competitors ... - Craft
ReViral is a biotechnology company developing drugs to treat RSV infections. It develops a small molecule inhibitor of RSV fusion RV521 to help children, the elderly and the immune …See details»
Big-name backers give ReViral $21M to move RSV drug into the …
Sep 10, 2015 · Edmond de Rothschild Investment Partners and OrbiMed have co-led a $21 million (€18.8 million) Series A round in ReViral, a London-based biotech that is edging a drug …See details»
Stuart Cockerill - Founder and Chief Scientific Officer @ ReViral ...
Stuart Cockerill PhD Chief Scientific Officer, Founder Stuart was the Principal Investigator on a Wellcome Trust funded Project, on behalf of ReViral. He obtained his PhD in Organic …See details»
ReViral and LianBio Announce Exclusive Collaboration and License ...
Mar 2, 2021 · LONDON & RESEARCH TRIANGLE PARK, N.C. & SHANGHAI & PRINCETON, N.J.-- ( BUSINESS WIRE )--ReViral Ltd., a clinical-stage biopharmaceutical company focused …See details»